SCHEMBL3366818

SCHEMBL3366818

CCOc1ccc(S(=O)(=O)N(CC(=O)N/N=C\c2ccccc2O)c2ccc(C)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OXTR P30559 5/20 1.00
AVPR1A P37288 3/20 1.00
MAPT P10636 6/20 0.71
LMNA P02545 2/20 0.71
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
POLB P06746 3/20 0.56
USP2 O75604 1/20 0.56
PKM P14618 1/20 0.56
ALOX12 P18054 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
ALDH1A1 P00352 2/20 0.55
KDM4E B2RXH2 1/20 0.55
RAB9A P51151 1/20 0.55
THRB P10828 1/20 0.54
MPI P34949 1/20 0.54
PTK2B Q14289 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367773 1.00 OXTR (1.00) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3366825 1.00 OXTR (1.00) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3366045 0.92 OXTR (1.00) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3366047 0.92 OXTR (1.00) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3369974 0.90 OXTR (0.82) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3363832 0.90 OXTR (0.82) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3366229 0.90 OXTR (0.82) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3363837 0.90 OXTR (0.82) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3369970 0.90 OXTR (0.82) OXTRAVPR1AMAPTLMNAMEN1
SCHEMBL3366273 0.90 OXTR (0.81) OXTRAVPR1AMAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP claimed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US claimed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US claimed
EP-1335901-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2003-08-20 EP claimed
WO-2002032864-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-04-25 WO claimed
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP disclosed
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US disclosed
EP-1335901-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2003-08-20 EP disclosed
WO-2002032864-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives OXTR, AVPR2, OPRL1 OXTR 1/4885AVPR1A 4/4885MAPT 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.